BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum

On September 21, 2017– BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, reported that Co-Chief Executive Officer Adi Mohanty will participate in a panel discussion at Cell & Gene Therapy CEO on Monday, September 25, 2017 in Boston (Press release, BioTime, SEP 21, 2017, View Source [SID1234520580]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The panel, titled "Financing Innovation: Attracting Investment" is at 2:00pm ET/11:00am PT. The discussion will be moderated by Rich Daly, Chairman and CEO of Neuralstem. Panelists include Mark Barrett, Entrepreneur-in-Residence, Frazier Healthcare Partners, David Grainger, Ph.D., CEO of Methuselah Health and Partner at Medicxi, and Nora Yang, Director, Portfolio Management & Strategic Operations at the National Center for Advancing Translational Sciences, National Institutes of Health.

Cell & Gene Therapy CEO is an off-the-record networking forum that brings together CEOs and decision makers in cell therapy, gene therapy, and regenerative medicine. Intimate discussion panels, keynotes and fireside chats feature thought leaders debating business model efficiencies, financing, regulatory issues, market access and reimbursement, novel partnerships, manufacturing, and delivery challenges. Healthcare investors and leading researchers also participate.

EAGLE PHARMACEUTICALS LICENSES JAPANESE RIGHTS FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE AND RAPID INFUSION INJECTION PRODUCTS TO SYMBIO PHARMACEUTICALS LIMITED

On September 20, 2017 Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") and SymBio Pharmaceuticals Limited ("SymBio") (Tokyo Stock Exchange/JASDAQ 4582) reported that the Company has licensed to SymBio rights under Eagle’s intellectual property to develop, market and sell Eagle’s bendamustine hydrochloride ("bendamustine HCl") ready-to-dilute ("RTD") and rapid infusion ("RI") injection products in Japan (Press release, Eagle Pharmaceuticals, SEP 20, 2017, View Source [SID1234540126]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SymBio will be responsible for securing regulatory approval of the RTD and RI injection products using the licensed technology in Japan with a target for approval of a product in 2020. SymBio currently markets TREAKISYM in Japan, a lyophilized powder formulation of bendamustine HCl indicated for chronic lymphocytic leukemia ("CLL"); relapsed or refractory low-grade Hodgkin’s lymphoma ("NHL"); mantle cell lymphoma ("MCL"); and as a first line treatment of low-grade NHL and MCL. According to SymBio, 12-month sales ended June 30, 2017 in Japan for TREAKISYM were $52 million, due to the approval of first line treatment for NHL and MCL in December 2016. SymBio has estimated that sales of TREAKISYM are estimated to grow to $90 million in 2018.

A 50 ml RI or rapid infusion presentation of bendamustine hydrochloride injection is currently marketed in the U.S. by Teva Pharmaceutical Industries, Ltd. ("Teva") as BENDEKA (bendamustine HCl) Injection. BENDEKA currently has a 97% market share of the bendamustine market, and Teva has forecasted the North American market for bendamustine to be approximately $600 – $660 million in sales in 2017. BENDEKA’s low volume infusion and short infusion time represents an important benefit to both patients and healthcare providers.

Pursuant to the terms of the license with SymBio, Eagle will receive a $12.5 million upfront milestone payment, and may be entitled to additional milestone payments upon approval and the achievement of cumulative sales thresholds. The Company will also receive royalties on future net sales of the licensed bendamustine products.

"This is an important example of the value of the Eagle portfolio to patients worldwide and a first step in expanding outside the U.S. for our differentiated products. We look forward to SymBio’s future approval and successful commercialization of bendamustine HCI in Japan," stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated, "In-licensing Eagle’s ready-to-dilute and rapid infusion injection products will enable SymBio to extend the product life and continue to maximize the value of TREAKISYM over the product life while bringing significant benefits to patients and healthcare providers in Japan."

Abbott Hosts Conference Call for Third-Quarter Earnings

On September 20, 2017 Abbott (NYSE: ABT) reported that they will announce its third-quarter 2017 financial results on Wednesday, Oct. 18, 2017, before the market opens (Press release, Abbott, SEP 20, 2017, View Source [SID1234520891]).

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott’s Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

On September 20, 2017 XBiotech Inc. (NASDAQ:XBIT) reported its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its interleukin-1 alpha antagonist, MABp1, for a Phase I single arm study evaluating the maximum tolerated dose of OnivydeⓇ (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia (Press release, XBiotech, SEP 20, 2017, View Source [SID1234520579]). The study will also assess efficacy using various secondary measures including changes in lean body mass, weight stability, IL-6 levels, overall and progression free survival as well as evaluation of the relationship between treatment tolerance and patient functional status.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Andrew Hendifar, M.D., Medical Oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and Co-Director of Pancreas Oncology, will be leading the study which is planned to enroll a total of 16 patients at the Cedars-Sinai Medical Center. Onivyde will be given intravenously with MABp1 and 5-fluorouracil/folinic acid every two weeks until disease progression.

Dr. Hendifar commented, "The results to date with treatment of MABp1 show much promise as an effective therapy in this setting. I look forward to evaluating this combination therapy to determine its safety and clinical benefit."

Despite decades of clinical trials, the prognosis for advanced pancreatic cancer is poor [1]. The 5-year survival has remained close to 5% and unchanged despite improvements in chemotherapeutics, surgical outcomes, and diagnostic techniques [1, 2]. Advanced pancreatic adenocarcinoma is characterized by progressive weight loss and nutritional deterioration [3]. It is estimated that up to 80% of these patients present with cachexia [4]. This syndrome has been linked not only to survival, but also to alterations in host defenses, functional ability, and quality of life. In a Phase III clinical study, MABp1 was found to improve clusters of symptoms that included reduced pain, fatigue, improved appetite and increased lean body mass. Patients that had these improvements were found to have reduced disease progression and serious adverse events, and about a three-fold improvement in survival.

Other than multi-agent cytotoxic therapy there have been no treatment advances for pancreatic cancer or its associated cachexia. Despite the availability of effective chemotherapy, only between 15-40% of pancreatic cancer patients are able to receive second line treatment. Importantly, cachexia and its associated fatigue and deconditioning, may explain the difficulty in providing continued therapy after progression in the first-line. It is hoped that MABp1 used in combination with Onivyde will help control disease, reduce symptoms and allow patients to receive treatment longer, thereby improving outcomes.

About True Human Therapeutic Antibodies
XBiotech’s True Human antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

On September 20, 2017 Novartis reported that the European Commission (EC) approved Rydapt (midostaurin) for two indications in rare, hard-to-treat cancers. Rydapt is approved for use in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adults with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive (Press release, Novartis, SEP 20, 2017, View Source [SID1234520575]). It was also cleared for use as monotherapy for the treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) or mast cell leukemia[1].

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The approval follows a positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on July 20, 2017 and applies to all 28 EU member states, plus Iceland, Liechtenstein and Norway. Rydapt represents the first and only targeted therapy for FMS-like tyrosine kinase 3 (FLT3)-mutated AML and the only treatment for three subtypes of SM, collectively known as advanced SM, in the EU, all of which have limited life expectancy and few treatment options. Rydapt represents the first major advancement for the treatment of patients with newly diagnosed FLT3-mutated AML in more than 25 years[2],[3].

"Novartis is proud that we can deliver Rydapt, a breakthrough medicine, to patients with serious and hard-to-treat diseases where there are few treatment options," said Bruno Strigini, CEO, Novartis Oncology. "For patients with FLT3-mutated AML, there have been no meaningful advancements in more than 25 years and with Rydapt they now have a targeted medicine that could significantly extend their lives."

For newly diagnosed FLT3-mutated AML, the approval is based on data from the RATIFY (CALGB 10603 [Alliance]) trial, which was conducted in collaboration with the Alliance for Clinical Trials in Oncology and 13 international cooperative groups. RATIFY is the largest trial to date among people with this specific type of AML and results of the trial were recently published in the New England Journal of Medicine (NEJM)[4]. The study showed a 23% reduction in the risk of death with Rydapt plus standard chemotherapy compared with placebo plus standard chemotherapy. Median overall survival of 74.7 months and 25.6 months, respectively (hazard ratio [HR] = 0.77, 95% confidence interval [CI], 0.63, 0.95; one-sided p=0.0078)[1].

In the RATIFY trial, the most frequent adverse reactions (incidence greater than or equal to 30%) in the Rydapt plus standard chemotherapy arm were febrile neutropenia, nausea, exfoliative dermatitis, vomiting, headache, petechiae (small red skin spots) and pyrexia. The most frequent Grade 3/4 adverse reaction (greater than or equal to 5%) was febrile neutropenia, lymphopenia, device-related infection, exfoliative dermatitis, hyperglycemia and nausea[1].

For advanced SM, the approval is based on two single-arm open-label multicenter trials, including the Phase II study (CPKC412D2201), the largest prospective trial ever conducted in this rare disorder, the results of which were also published in NEJM[5]. The efficacy of Rydapt was established using modified Valent criteria, with patients demonstrating an overall response rate, defined as a major or partial response, of 59.6% (95% [CI], 48.6, 69.8%). Efficacy was also assessed in a post-hoc analysis using the 2013 International Working Group-Myeloproliferative Neoplasms Research and Treatment-European Competence Network on Mastocytosis (IWG-MRT-ECNM) consensus criteria (n=113). This assessment estimated an overall response rate of 28.3% (95% CI, 20.2, 37.6)[1].

In advanced SM, the most frequent adverse reactions were nausea, vomiting, diarrhea, peripheral edema and fatigue. The most frequent Grade 3/4 adverse reactions were fatigue, sepsis, pneumonia, febrile neutropenia and diarrhea[1].

Rydapt Ongoing Clinical Development
In order to further investigate the potential of Rydapt in AML, Novartis is planning a Phase III study in newly diagnosed AML patients without a FLT3 mutation (wildtype).

About AML
AML is the most common acute leukemia, or blood cancer, in adults; it accounts for approximately 25% of all adult leukemias worldwide, with the highest incidence rates occurring in the US, Europe and Australia[6]. It also has the lowest survival rate of all adult leukemias[6].

In AML, white blood cells are not able to mature and instead build up an accumulation of "blasts," blocking room for normal blood cells[7]. Mutations in specific genes, such as FLT3, are found in many cases of the disease[8]. Genetic testing for mutations in newly diagnosed AML patients can help to determine prognosis and potential treatment strategies[9].

In the EU, there are more than 18,000 estimated new cases of AML diagnosed each year[10]. Approximately one-third of AML patients have a FLT3 gene mutation[8]. FLT3 is a type of cell-surface receptor, which plays a role in increasing the number of certain blood cells[11]. The FLT3 gene mutation can result in faster disease progression, higher relapse rates and lower rates of survival than other forms of AML[8],[11],[12].

About Advanced SM
In advanced SM, the uncontrolled growth of neoplastic mast cells causes organ damage (e.g., liver dysfunction), low blood counts and weight loss[13]. People with the disease also suffer from debilitating systemic symptoms such as pruritus (severe itching of the skin) caused by mast cells releasing inflammatory mediators, such as histamine, into the blood[13].

The uncontrolled proliferation of mast cells is caused in many people by a KIT gene mutation – the most common mutation, encoding the D816V substitution, occurs in approximately 90% of patients[14]. The KIT gene mutation results in activation of the KIT enzyme, which triggers the abnormal proliferation and survival of mast cells[15].

About Rydapt (midostaurin)
Rydapt (midostaurin) is an oral, targeted therapy, a type of treatment that interferes with certain pathways that are involved in the growth, progression and spread of cancer. Rydapt inhibits multiple kinases, including FLT3, which help regulate many essential cell processes, interrupting cancer cells’ ability to grow and multiply. Rydapt induces cell death in leukemic cells expressing FLT3 ITD or TKD mutant receptors, or in cells overexpressing FLT3 wildtype receptors[1].

Rydapt also inhibits the activity of the kinase KIT (wild type and D816V mutant), inhibiting mast cell proliferation, survival and histamine release. In addition, Rydapt inhibits several other receptor tyrosine kinases such as PDGFR alpha/ß, VEGFR2, and members of the serine/threonine kinase PKC family, inhibiting signaling of the respective growth factors in cells, resulting in growth arrest[1].

During the past decade, targeted therapies have become known for extending the lives of patients across multiple tumor types.

Rydapt is also approved in the US, Switzerland and Canada. Indications vary by country and not all indications are available in every country. The safety and efficacy profile of Rydapt has not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that Rydapt will become commercially available for additional indications anywhere else in the world.

Rydapt Important Safety Information FROM THE RYDAPT EU SmPC
Patients who are allergic to midostaurin or any of the ingredients in Rydapt should not take Rydapt. If a patient taking Rydapt develops signs of an allergic reaction, they should seek medical help immediately. Signs of an allergic reaction include difficulty breathing or swallowing, dizziness, swelling of the face, lips, tongue or throat, severe itching of the skin, with a red rash or raised bumps.

The following medicines should be avoided during treatment with Rydapt: medicines used to treat tuberculosis, such as rifampicin; medicines used to treat epilepsy, such as carbamazepine or phenytoin; enzalutamide, a medicine used to treat prostate cancer; St. John’s Wort, a herbal medicine used to treat depression. Patients should tell their doctor about all the medicines they are taking, have recently taken or might take.

Before taking Rydapt, patients should tell their doctor if they have any infections, a heart disorder or lung problems. Patients on Rydapt who experience the following symptoms should get medical help right away: fever, sore throat or mouth ulcers (signs of infections); new or worsening symptoms such as fever, cough with or without mucous, chest pain, trouble breathing or shortness of breath (signs of infections or lung problems); chest pain or discomfort, light headedness, fainting, dizziness, blue discoloration of the lips, hands or feet, shortness of breath, or swelling of the lower limbs (edema) or skin (signs of heart problems). Depending on the severity, doctors may adjust, temporarily stop or completely discontinue treatment with Rydapt.

For patients on Rydapt, regular blood tests should be performed in order to monitor the amount of blood cells (white blood cells, red blood cells and platelets) and electrolytes (e.g. calcium, potassium, magnesium). Patients’ heart and lung function will be checked regularly.

Rydapt is not recommended during pregnancy because it may harm an unborn baby. Pregnancy testing should be done before treatment start to make sure the patient is not pregnant. Effective birth control should be used during treatment with Rydapt and for at least four months after stopping Rydapt. If a hormonal contraceptive is used, a barrier method, such as a condom or a diaphragm must also be used. Rydapt may harm a baby. Women should not breastfeed during treatment with Rydapt and for at least four months after stopping the treatment. Rydapt may reduce fertility in women and men.

Rydapt contains alcohol, which may be harmful for patients with alcohol related problems, epilepsy or liver problems, or who are pregnant or breast feeding. Rydapt contains macrogolglycerol hydroxystearate, which may cause stomach discomfort and diarrhea.

Some side effects in patients with AML could be serious: weakness, spontaneous bleeding or bruising, frequent infections with signs such as fever, chills, sore throat or mouth ulcers (signs of a low level of blood cells); severe shortness of breath, labored and unusually rapid breathing, dizziness, light headedness, confusion and extreme tiredness (signs of acute respiratory distress syndrome); infections, fever, low blood pressure, decreased urination, rapid pulse, rapid breathing (signs of sepsis or neutropenic sepsis).

Some side effects in patients with ASM, SM-AHN and mast cell leukemia could be serious: weakness, spontaneous bleeding or bruising, frequent infections with signs such as fever, chills, sore throat or mouth ulcers (signs of a low level of blood cells); fever, cough, difficult or painful breathing, wheezing, chest in pain when breathing (signs of pneumonia); infections, fever, dizziness, light headedness, decreased urination, rapid pulse, rapid breathing (signs of sepsis or neutropenic sepsis); vomiting of blood, black or bloody stools (signs of gastrointestinal bleeding).

Please see full prescribing information for Rydapt